{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:42:48Z","timestamp":1793292168297,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Major science and technology projects of Gansu Province","award":["23ZDFA014"],"award-info":[{"award-number":["23ZDFA014"]}]},{"name":"Isotope and Drug Innovation Fund of National Engineering Research Center for Isotopes and Drugs","award":["TWSCX-2023-CXJJ-3-1"],"award-info":[{"award-number":["TWSCX-2023-CXJJ-3-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\n              <jats:sup>68<\/jats:sup>Ga-FAPI (fibroblast activation protein inhibitor) is a novel and highly promising radiotracer for PET\/CT imaging. It has shown significant tumor uptake and high sensitivity in lesion detection across a range of cancer types. We aimed to compare the diagnostic value of <jats:sup>68<\/jats:sup>Ga-FAPI and <jats:sup>18<\/jats:sup>F-FDG PET\/CT in common gynecological malignancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study included 35 patients diagnosed with common gynecological tumors, including breast cancer, ovarian cancer, and cervical cancer. Among the 35 patients, 27 underwent PET\/CT for the initial assessment of tumors, while 8 were assessed for recurrence detection. The median and range of tumor size and maximum standardized uptake values (SUV<jats:sub>max<\/jats:sub>) were calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Thirty-five patients (median age, 57 years [interquartile range], 51\u201365 years) were evaluated. In treatment-naive patients (<jats:italic>n<\/jats:italic>\u2009=\u200927), <jats:sup>68<\/jats:sup>Ga-FAPI PET\/CT led to upstaging of the clinical TNM stage in five (19%) patients compared with <jats:sup>18<\/jats:sup>F-FDG PET\/CT. No significant difference in tracer uptake was observed between <jats:sup>18<\/jats:sup>F-FDG and <jats:sup>68<\/jats:sup>Ga-FAPI for primary lesions: breast cancer (7.2 vs. 4.9, <jats:italic>P<\/jats:italic>\u2009=\u20090.086), ovarian cancer (16.3 vs. 15.7, <jats:italic>P<\/jats:italic>\u2009=\u20090.345), and cervical cancer (18.3 vs. 17.1, <jats:italic>P<\/jats:italic>\u2009=\u20090.703). For involved lymph nodes, <jats:sup>68<\/jats:sup>Ga-FAPI PET\/CT demonstrated a higher SUV<jats:sub>max<\/jats:sub> for breast cancer (9.9 vs. 6.1, <jats:italic>P<\/jats:italic>\u2009=\u20090.007) and cervical cancer (6.3 vs. 4.8, <jats:italic>P<\/jats:italic>\u2009=\u20090.048), while no significant difference was noted for ovarian cancer (7.0 vs. 5.9, <jats:italic>P<\/jats:italic>\u2009=\u20090.179). Furthermore, <jats:sup>68<\/jats:sup>Ga-FAPI PET\/CT demonstrated higher specificity and accuracy compared to <jats:sup>18<\/jats:sup>F-FDG PET\/CT for detecting metastatic lymph nodes (100% vs. 66%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; 94% vs. 80%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). In contrast, sensitivity did not differ significantly (97% vs. 86%, <jats:italic>P<\/jats:italic>\u2009=\u20090.125). For most distant metastases, <jats:sup>68<\/jats:sup>Ga-FAPI exhibited a higher SUV<jats:sub>max<\/jats:sub> than <jats:sup>18<\/jats:sup>F-FDG in bone metastases (12.9 vs. 4.9, <jats:italic>P<\/jats:italic>\u2009=\u20090.036).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n              <jats:sup>68<\/jats:sup>Ga-FAPI PET\/CT demonstrated higher tracer uptake and was superior to <jats:sup>18<\/jats:sup>F-FDG PET\/CT in detecting primary and metastatic lesions in patients with common gynecological malignancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ChiCTR, ChiCTR2100044131. Registered 10 October 2022, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.chictr.org.cn\" ext-link-type=\"uri\">https:\/\/www.chictr.org.cn<\/jats:ext-link>, ChiCTR2100044131.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40644-025-00843-7","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:53:18Z","timestamp":1740725598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Head-to-head comparison of 18F-FDG and 68Ga-FAPI PET\/CT in common gynecological malignancies"],"prefix":"10.1186","volume":"25","author":[{"given":"Tengfei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhuo","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchu","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"843_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"843_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11307-018-1181-3","volume":"21","author":"K Paydary","year":"2019","unstructured":"Paydary K, Seraj SM, Zadeh MZ, et al. The evolving role of FDG-PET\/CT in the diagnosis, staging, and treatment of breast Cancer. Mol Imaging Biol. 2019;21:1\u201310.","journal-title":"Mol Imaging Biol"},{"key":"843_CR3","first-page":"7276","volume":"24","author":"J Sun","year":"2020","unstructured":"Sun J, Cui XW, Li YS, et al. The value of 18F-FDG PET\/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Eur Rev Med Pharmacol Sci. 2020;24:7276\u201383.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"843_CR4","doi-asserted-by":"crossref","unstructured":"Olthof EP, Wenzel HHB, van der Velden J, Stalpers LJA, Mom CH, van der Aa MA. (2024) Treatment strategies guided by [18F]FDG-PET\/CT in patients with locally advanced cervical Cancer and [18F]FDG-Positive lymph nodes. Cancers (Basel) 16.","DOI":"10.3390\/cancers16040717"},{"key":"843_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cpet.2019.11.001","volume":"15","author":"S Hess","year":"2020","unstructured":"Hess S, Scholtens AM, Gormsen LC. Patient Preparation and Patient-related challenges with FDG-PET\/CT in infectious and inflammatory disease. PET Clin. 2020;15:125\u201334.","journal-title":"PET Clin"},{"issue":"Suppl 1","key":"843_CR6","first-page":"S125","volume":"31","author":"P Lind","year":"2004","unstructured":"Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S125\u2013134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"843_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62:160\u20137.","journal-title":"J Nucl Med"},{"key":"843_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, et al. A Tumor-Imaging method targeting Cancer-Associated fibroblasts. J Nucl Med. 2018;59:1423\u20139.","journal-title":"J Nucl Med"},{"key":"843_CR9","doi-asserted-by":"publisher","first-page":"854658","DOI":"10.3389\/fonc.2022.854658","volume":"12","author":"R Huang","year":"2022","unstructured":"Huang R, Pu Y, Huang S, et al. FAPI-PET\/CT in Cancer imaging: A potential novel molecule of the century. Front Oncol. 2022;12:854658.","journal-title":"Front Oncol"},{"key":"843_CR10","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","volume":"48","author":"K Dendl","year":"2021","unstructured":"Dendl K, Koerber SA, Finck R, et al. (68)Ga-FAPI-PET\/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021;48:4089\u2013100.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"843_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, et al. (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of Cancer. J Nucl Med. 2019;60:801\u20135.","journal-title":"J Nucl Med"},{"key":"843_CR12","doi-asserted-by":"publisher","first-page":"e194003","DOI":"10.1148\/rycan.2019194003","volume":"1","author":"DK Hathi","year":"2019","unstructured":"Hathi DK, Jones EF. (68)Ga FAPI PET\/CT: tracer uptake in 28 different kinds of Cancer. Radiol Imaging Cancer. 2019;1:e194003.","journal-title":"Radiol Imaging Cancer"},{"key":"843_CR13","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2967\/jnumed.123.265530","volume":"64","author":"X Chen","year":"2023","unstructured":"Chen X, Wang S, Lai Y, et al. Fibroblast activation protein and Glycolysis in lymphoma diagnosis: comparison of (68)Ga-FAPI PET\/CT and (18)F-FDG PET\/CT. J Nucl Med. 2023;64:1399\u2013405.","journal-title":"J Nucl Med"},{"key":"843_CR14","doi-asserted-by":"publisher","first-page":"875081","DOI":"10.3389\/fonc.2022.875081","volume":"12","author":"H Liu","year":"2022","unstructured":"Liu H, Hu Z, Yang X, Dai T, Chen Y. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG uptake in esophageal Cancer. Front Oncol. 2022;12:875081.","journal-title":"Front Oncol"},{"key":"843_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, et al. (68)Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-Containing FAP-Targeting agents in patients with various cancers. J Nucl Med. 2019;60:386\u201392.","journal-title":"J Nucl Med"},{"key":"843_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1148\/radiol.211424","volume":"303","author":"L Wang","year":"2022","unstructured":"Wang L, Tang G, Hu K, et al. Comparison of (68)Ga-FAPI and (18)F-FDG PET\/CT in the evaluation of advanced lung Cancer. Radiology. 2022;303:191\u20139.","journal-title":"Radiology"},{"key":"843_CR17","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00259-022-06096-x","volume":"50","author":"S Liu","year":"2023","unstructured":"Liu S, Feng Z, Xu X, et al. Head-to-head comparison of [(18)F]-FDG and [(68) Ga]-DOTA-FAPI-04 PET\/CT for radiological evaluation of platinum-sensitive recurrent ovarian cancer. Eur J Nucl Med Mol Imaging. 2023;50:1521\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"843_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3892\/ol.2015.3151","volume":"10","author":"M Zhang","year":"2015","unstructured":"Zhang M, Xu L, Wang X, Sun B, Ding J. Expression levels of Seprase\/FAPalpha and DPPIV\/CD26 in epithelial ovarian carcinoma. Oncol Lett. 2015;10:34\u201342.","journal-title":"Oncol Lett"},{"key":"843_CR19","doi-asserted-by":"publisher","first-page":"8685","DOI":"10.1007\/s13277-015-3594-9","volume":"36","author":"YY Jung","year":"2015","unstructured":"Jung YY, Lee YK, Koo JS. Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer. Tumour Biol. 2015;36:8685\u201395.","journal-title":"Tumour Biol"},{"key":"843_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s00259-020-04947-z","volume":"48","author":"I Sonni","year":"2021","unstructured":"Sonni I, Lee-Felker S, Memarzadeh S, et al. (68)Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation. Eur J Nucl Med Mol Imaging. 2021;48:924\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"843_CR21","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00259-021-05203-8","volume":"48","author":"K Dendl","year":"2021","unstructured":"Dendl K, Koerber SA, Adeberg S, et al. Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:2059\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"843_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RLU.0000000000003968","volume":"47","author":"X Zhang","year":"2022","unstructured":"Zhang X, Song W, Qin C, et al. Uterine uptake of 68Ga-FAPI-04 in uterine pathology and physiology. Clin Nucl Med. 2022;47:7\u201313.","journal-title":"Clin Nucl Med"},{"key":"843_CR23","doi-asserted-by":"publisher","first-page":"1358070","DOI":"10.3389\/fonc.2024.1358070","volume":"14","author":"T Li","year":"2024","unstructured":"Li T, Zhang J, Yan Y, Tan M, Chen Y. Applications of FAPI PET\/CT in the diagnosis and treatment of breast and the most common gynecologic malignancies: a literature review. Front Oncol. 2024;14:1358070.","journal-title":"Front Oncol"},{"key":"843_CR24","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1097\/RLU.0000000000004523","volume":"48","author":"S Zheng","year":"2023","unstructured":"Zheng S, Lin J, Zhu Y, et al. 68Ga-FAPI versus 18F-FDG PET\/CT in evaluating newly diagnosed breast Cancer patients: A Head-to-Head comparative study. Clin Nucl Med. 2023;48:e104\u20139.","journal-title":"Clin Nucl Med"},{"key":"843_CR25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266652","author":"N Hirmas","year":"2024","unstructured":"Hirmas N, Hamacher R, Sraieb M, et al. Diagnostic accuracy of (68)Ga-FAPI versus (18)F-FDG PET in patients with various malignancies. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.123.266652.","journal-title":"J Nucl Med"},{"key":"843_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1148\/radiol.213118","volume":"304","author":"L Lan","year":"2022","unstructured":"Lan L, Zhang S, Xu T, et al. Prospective comparison of (68)Ga-FAPI versus (18)F-FDG PET\/CT for tumor staging in biliary tract cancers. Radiology. 2022;304:648\u201357.","journal-title":"Radiology"},{"key":"843_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/RLU.0000000000004604","volume":"48","author":"H Liu","year":"2023","unstructured":"Liu H, Yang X, Liu L, Qu G, Chen Y. Comparison of 18 F-FDG and 68 Ga-FAPI-04 uptake in postoperative Re-evaluation of gastric, duodenal, and colorectal cancers. Clin Nucl Med. 2023;48:304\u20138.","journal-title":"Clin Nucl Med"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00843-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:53:24Z","timestamp":1740725604000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00843-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00843-7","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Affiliated Hospital of Southwest Medical University (Ethics committee approval No.: KY2022114; Clinical trial registration No.: ChiCTR2100044131). All procedures involving human participants were performed in accordance with the ethical standards of the institutional committee, as well as the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any animal experiments. Informed consent was obtained from all participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}